40 | ||||
Around | ||||
4,000 | Around | |||
Around | ||||
production sites in around 20 countries | ||||
More than | 120,000 | |||
dialysis centers in around 50 countries |
332,000 employees
patients worldwide 52M Around
dialysis treatments in 2023
The Company at a Glance
Financial Figures (in BN €)
19.45
Revenue
0.76 1.74
Net income1 exclu- | Operating income |
ding special items | excluding special |
and PRF2 | items and PRF2 |
Who We Are
Fresenius Medical Care is the world's leading provider of products and services for people with renal disease. We serve more than 332,000 dialysis patients worldwide and provide products in around
150 countries. Our goal is not only to treat, but also to innovate, to improve the lives of those impacted by kidney disease.
Vision - Mission - Strategy | Chief Executive Officer and | |
Creating a future worth living. For | Chair of the Management Board | |
patients. Worldwide. Every day. | Helen Giza | |
This vision guides our company | ||
to provide people across the renal | ||
care continuum with outstanding | ||
healthcare and high-quality | ||
products. We aim to use our | ||
innovative products and services | ||
to offer sustainable solutions at a | ||
reliable cost around the world. Our | ||
commitment to sustainability is an | ||
integral part of our strategy. | ||
- Net income attributable to shareholders of Fresenius Medical Care AG.
-
For FY 2023, special items include the costs related to the FME25 program, the Humacyte investment remeasurement, the costs associated with the legal form conversion and the effects from legacy portfolio optimization. For FY 2022,
special items include the costs related to the FME25 program, the impact of the war in Ukraine, the impact of hyperinflation in Turkiye, the Humacyte investment remeasurement and the net gain related to InterWell Health. Additionally,
FY 2022 was adjusted for the U.S. Provider Relief Funding (PRF). For further details please see the reconciliation attached to the press release for the 4th quarter 2023.
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
FMC - Fresenius Medical Care AG & Co. KGaA published this content on 20 February 2024 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 04 March 2024 08:48:03 UTC.